Verition Fund Management
CTXR icon

Verition Fund Management’s Citius Pharmaceuticals CTXR Stock Holding History

Verition Fund Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,352
Closed -$101K – 2402
2023
Q2 		$101K Buy
+3,352
New +$110K ﹤0.01% 1976
2021
Q3 		– Sell
-2,103
Closed -$183K – 1977
2021
Q2 		$183K Buy
+2,103
New +$126K ﹤0.01% 1616

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Verition Fund Management's CTXR Position: Q3 2023 in Review

Verition Fund Management sold out of Citius Pharmaceuticals (CTXR) in Q3 2023, closing a stake of 3,352 shares — an estimated $101K sold.

Verition Fund Management first reported a position in CTXR in Q2 2021 and held it in 2 quarters. The position peaked at $183K in Q2 2021. 74 funds tracked by Wall St. Rank hold CTXR as of Q3 2023.

  • Verition Fund Management reported no remaining Citius Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Verition Fund Management sold 3,352 Citius Pharmaceuticals shares in Q3 2023, an estimated $101K.
  • Verition Fund Management first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Verition Fund Management's Citius Pharmaceuticals position peaked at $183K in Q2 2021.
  • 74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2023.

Based on Verition Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.